Bio Medica Laboratories IPO is an upcoming SME IPO that has attracted investor interest due to the company’s strong growth in the pharmaceutical and injectable medicine segment. The company manufactures parenteral medicines for both human and veterinary healthcare markets.
The IPO will open on May 21, 2026, and close on May 25, 2026. The company plans to raise funds through a book build issue and list on NSE SME. In this detailed IPO Updates review, we will cover Bio Medica Laboratories IPO date, GMP, review, price band, allotment details, financials, strengths, risks, and whether investors should apply or avoid this IPO.
About Bio Medica Laboratories Limited
Bio Medica Laboratories Limited is one of the leading manufacturers of parenteral medicines (injectable products) in India.
The company develops and manufactures:
- Liquid Injections
- Dry Powder Injections
- Veterinary Injectables
- Export Injectables
- Human Healthcare Injectables
Its products are available in different packaging formats such as:
- Ampoules
- Vials
The company follows:
- GMP (Good Manufacturing Practices)
- GLP (Good Laboratory Practices)
Bio Medica Laboratories focuses on producing high-quality and safe pharmaceutical products for domestic and international healthcare markets.
The company operates its manufacturing facility in Indore, Madhya Pradesh, and has built a strong presence in the injectable medicine segment.
| IPO Open Date May 21, 2026 | IPO Close Date May 25, 2026 | Face Value ₹10 Per Equity Share | IPO Price Band Yet to be Announced |
Bio Medica Laboratories IPO Details
| Particulars | Details |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | Yet to be Announced |
| Issue Size | Approx ₹[.] Crores |
| Fresh Issue | Approx 33,95,000 Equity Shares |
| Offer for Sale | 3,76,800 Equity Shares |
| IPO Type | Book Build Issue |
| Listing Exchange | NSE SME |
| Allotment Date | May 26, 2026 |
| Listing Date | May 28, 2026 |
Bio Medica Laboratories IPO Market Lot
The market lot details are yet to be announced by the company.
| Application Type | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | TBA | TBA | TBA |
| Retail Maximum | TBA | TBA | TBA |
| S-HNI Minimum | TBA | TBA | TBA |
| B-HNI Minimum | TBA | TBA | TBA |
IPO Reservation Details
| Investor Category | Reservation |
|---|---|
| QIB | 50% |
| Retail Investors | 35% |
| HNI/NII | 15% |
Bio Medica Laboratories IPO Important Dates
| Event | Date |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Basis of Allotment | May 26, 2026 |
| Refund Initiation | May 27, 2026 |
| Credit to Demat Account | May 27, 2026 |
| Listing Date | May 28, 2026 |
| IPO Cut-Off Time | May 25, 2026 – 5 PM |
Promoters of Bio Medica Laboratories
The promoters of the company are:
- Mr. Mukesh Mehta
- Mr. Pradeep Mehta
| Particulars | Shares | Holding |
|---|---|---|
| Pre-Issue Holding | 91,80,001 Shares | 99.99% |
| Post-Issue Holding | 1,25,74,801 Shares | Updated After Listing |
Objects of the IPO
The company plans to use IPO proceeds for expansion and debt repayment.
| Purpose | Amount |
|---|---|
| Repayment of Loan | ₹7.25 Crores |
| New Manufacturing Facility Setup | ₹24.81 Crores |
| General Corporate Purposes | Remaining Amount |
The company aims to improve production capacity through the expansion of its existing manufacturing infrastructure.
Bio Medica Laboratories Financial Report
The company has shown impressive financial growth in recent years.
| Year | Revenue | Expenses | PAT | Assets |
|---|---|---|---|---|
| 2023 | ₹16.25 Cr | ₹15.80 Cr | ₹0.33 Cr | ₹17.57 Cr |
| 2024 | ₹15.34 Cr | ₹11.69 Cr | ₹2.50 Cr | ₹19.53 Cr |
| 2025 | ₹38.33 Cr | ₹25.18 Cr | ₹9.79 Cr | ₹39.12 Cr |
| Nov 2025 | ₹28.63 Cr | ₹16.95 Cr | ₹8.66 Cr | ₹65.17 Cr |
The company reported strong growth in both revenue and profitability.
Key Financial Highlights
- Revenue increased from ₹15.34 Cr to ₹38.33 Cr
- Profit rose from ₹2.50 Cr to ₹9.79 Cr
- Assets increased significantly over the years
The strong financial performance may support long-term growth potential.
Bio Medica Laboratories IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE | 99.59% |
| ROCE | 48.20% |
| EBITDA Margin | 39.83% |
| PAT Margin | 25.64% |
| Debt to Equity Ratio | 1.02 |
| EPS | ₹10.67 |
| RoNW | 99.59% |
| NAV | ₹16.05 |
The company has reported strong return ratios and healthy profit margins.
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW | NAV | Income |
|---|---|---|---|---|---|
| Zenotech Laboratories Ltd | 0.92 | – | 6.01% | 15.76 | ₹5.61 Cr |
| Shukra Pharmaceuticals Ltd | 0.22 | 47.57 | 15.90% | 1.43 | ₹9.58 Cr |
Strengths of Bio Medica Laboratories IPO
1. Strong Pharmaceutical Sector Presence
The company operates in the growing injectable medicine market.
2. Strong Financial Growth
Revenue and profit growth have improved significantly in FY2025.
3. Manufacturing Expansion
IPO proceeds will support new manufacturing facility expansion.
4. Diversified Product Portfolio
The company serves both human and veterinary healthcare markets.
5. High Profit Margins
The company has reported healthy EBITDA and PAT margins.
Risks of the IPO Market Rumors
1. SME IPO Risk
SME IPOs generally carry higher volatility and lower liquidity.
2. Regulatory Risk
Pharmaceutical companies face strict compliance and regulatory requirements.
3. Competition
The injectable medicine market is highly competitive.
4. Debt Levels
The company’s debt-to-equity ratio remains slightly elevated.
Bio Medica Laboratories IPO GMP Market Rumors
The Grey Market Premium (GMP) of this IPO may fluctuate daily depending on market demand and subscription levels. Investors should avoid relying only on GMP while making investment decisions.
Should You Appl Laboratories IPO? Market Rumors
Based on the company’s strong financial growth, expanding manufacturing capability, and presence in the pharmaceutical sector, the IPO appears attractive for long-term investors.
Positive Factors
- Strong revenue growth
- High profit margins
- Expansion plans
- Growing pharmaceutical industry
Negative Factors
- SME IPO volatility
- Regulatory risks
- Competition in the pharma sector
Long-term investors with moderate to high risk appetite may consider this IPO after proper research.
IPO Lead Manager
Narnolia Financial Services Ltd.
Company Address
Bio Medica Laboratories Ltd.
Plot No. 11B-11C, Sector-E, Sanwer Road
Industrial Area, Industrial Estate (Indore)
Indore, Madhya Pradesh – 452015
Phone: +91 7314102751
Email: companysecretary@biomedica.co.in
Website: http://www.biomedica.co.in/
IPO Registrar
Skyline Financial Services Pvt. Ltd.
Phone: 02228511022
Email: ipo@skylinerta.com
Website: https://www.skylinerta.com/ipo.php
Bio Medica Laboratories IPO FAQs
What is BioMedica Laboratories’ IPO?
It is an SME IPO through which the company plans to raise funds via a fresh issue and offer for sale.
When will Bio Medica Laboratories IPO open?
The IPO will open on May 21, 2026, and close on May 25, 2026.
What is the IPO Price Band?
The price band is yet to be announced.
What is the IPO Allotment Date?
The allotment date is May 26, 2026.
What is the Listing Date?
The IPO will list on NSE SME on May 28, 2026.
Disclaimer
The information shared here is intended solely for educational and general awareness purposes. Any securities, investments, or IPO-related details mentioned should not be interpreted as financial advice or investment recommendations. Readers are encouraged to conduct their own independent research or seek guidance from a qualified financial professional before making investment decisions.
IPO-related updates are provided for informational use only. Market trends, past performance, or investor interest do not ensure future outcomes. We are not registered with SEBI. Investments in IPOs and the securities market involve inherent risks, and individuals should carefully evaluate their financial situation or consult a certified financial advisor before investing.
